Robert Adelman, MD


Robert Adelman has a 30-year history of founding, investing in, and managing companies in the life sciences sector. He received his undergraduate degree from University of California at Berkeley and his medical degree from Yale University. Following a residency at Cornell University Medical Center, he practiced surgery in New York and New Jersey. Before founding venBio, Dr. Adelman had a seven-year tenure as a private equity partner at OrbiMed Advisors. There, he was part of a team that invested $1.1B in both private and public companies across three venture capital funds. The co-founder of several biotechnology companies, he led Fund I’s investments into Aragon Pharmaceuticals, where he joined the board of directors and remained until the company’s acquisition by Johnson & Johnson. He also led the investment into Seragon Pharmaceuticals, where he joined the board of directors and remained until the company’s acquisition by Genentech/Roche. Adelman co-led Fund I’s investments with Dr. Goodman into Solstice Biologics and Heart Metabolics and currently serves on the board of both companies.

Back